API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds will focus on advancing first-in-category investigational products Ovaprene, an intravaginal ring that releases ascorbic acid and ferrous gluconate contraceptive, and Sildenafil Cream, a potential first FDA-approved treatment for female sexual arousal disorder.
Lead Product(s): Ferrous Gluconate,Ascorbic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: XOMA
Deal Size: $22.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 30, 2024
Details:
Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive, prevented essentially all sperm from entering the cervical canal across all women and all cycles evaluated.
Lead Product(s): Ferrous Gluconate,Ascorbic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipeline.
Lead Product(s): Ferrous Gluconate,Ascorbic Acid
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avomeen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 01, 2020
Details:
Publication of a literature review article by Biology of Reproduction identifies and reviews 10 postcoital test studies of vaginal contraceptives involving 9 test products, including Daré’s Ovaprene, currently under a license agreement with Bayer.
Lead Product(s): Ferrous Gluconate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ovaprene
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020